Bavarian Nordic

Bavarian Nordic launches VIMKUNYA in the UK for the Prevention of Chikungunya, for individuals aged 12 years and older

3 September 2025 -- London, UK -- Bavarian Nordic A/S announced today the official UK launch of the VIMKUNYA® chikungunya vaccine (recombinant, absorbed). This follows the recent approval by the Medicines and Healthcare products Regulatory Agency (MHRA) in May 2025 and the recent advice published on chikungunya from the Joint Committee on Vaccination and Immunisation...

Bavarian Nordic Secures Vaccine Order From European Country After Confirmed Monkeypox Cases

COPENHAGEN, Denmark, May 19, 2022 - Bavarian Nordic A/S (OMX: BAVA) announced today that the Company has secured a contract with an undisclosed European country to supply its IMVANEX smallpox vaccine in response to new cases of monkeypox evolving during May 2022.
Bavarian Nordic GmbH Fraunhoferstrasse 13 D-82152 Martinsried

+49 89 255 446 300